6533b834fe1ef96bd129cbbc
RESEARCH PRODUCT
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.
Biselli MAndreone PGramenzi ATrevisani FCursaro CRossi CRiccaRosellini SCalogero Camma'Lorenzini SStefanini GfGasbarrini GBernardi M.subject
Liver CirrhosisMaleCirrhosisTime FactorsPrognostic systemGastroenterologyOily chemoembolizationHepatic ArteryCause of DeathAscitesValidationMedicineStage (cooking)CIRRHOSISUnivariate analysisAntibiotics AntineoplasticLiver NeoplasmsGastroenterologyLiver-TransplantationMiddle AgedHEPATOCELLULAR CARCINOMA; CIRRHOSIS; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; SURVIVAL; SIDE EFFECTSPrognosisTreatment OutcomeItalyRandomized controlled trialHepatocellular carcinomaSURVIVALFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularMultivariate-analysiTransarterial chemoembolizationInternal medicineSIDE EFFECTSCarcinomaHumansHEPATOCELLULAR CARCINOMAChemoembolization TherapeuticTranscatheter arterial chemoembolizationSurvival analysisAgedEpirubicinNeoplasm StagingCirrhosiHepatologybusiness.industrymedicine.diseaseSurvival AnalysisSurgeryLipiodol chemoembolizationTRANSCATHETER ARTERIAL CHEMOEMBOLIZATIONCase-Control StudiesMultivariate AnalysisbusinessFollow-Up Studiesdescription
Background & Aims: Transcatheter arterial chemoembolization (TACE) currently is used as a palliative treatment for patients with unresectable hepatocellular carcinoma (HCC), but its efficacy still is debated. Our aim was to assess the impact of TACE on patient survival and to identify prognostic factors for survival. Methods: Fifty-six cirrhotic patients with unresectable HCC undergoing at least :1 course of TACE were matched 1:1. for sex, age (in 5-year periods), parameters of Child-Pugh score, Okuda stage, and tumor type with a control group who had received only supportive care. Results: The 2 groups were comparable for cause of cirrhosis, alpha-fetoprotein serum levels, and Cancer of the Liver Italian Program (CLIP) score. The 56 patients in the TACE group received a total of 123 treatment courses. The median follow-up period was 16 months (range, 1-67 mo) in the TACE group and 5 months (range, 1-77 mo) in the supportive care group. Survival rates at 12, 24, and 30 months in patients receiving TACE were 74.3%, 52.1%, and 38.8% respectively, with a median survival time of 25 month whereas in supportive care patients the rates we 39.4%, 25.4%, and 19%, respectively, with a median survival time of 7 months (P =.0004). At univariate analysis, TACE, tumor type, presence of ascites, alpha-fetoprotein serum level, CLIP score, and Okuda stage were associated significantly with survival. Only TACE and CLIP score proved to be independent predictors of survival at multivariate analysis. Conclusions: TACE is an effective therapeutic option for cirrhotic patients with unresectable HCC and a CLIP score of 3 or less.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2005-01-01 | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association |